Pembrolizumab Shows Promise for NSCLC

    Cancer Discovery
    |April 22, 2015
    PubMed
    Summary

    Pembrolizumab offers improved outcomes for advanced non-small cell lung cancer patients and is well-tolerated. High programmed death-ligand 1 (PD-L1) expression (≥50%) predicts better treatment efficacy.

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.2K
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.5K